Immunotherapy

About This Classification

Immunotherapy involves the use of many active agents such as cells, cytokines or vaccines (among others). These agents are used to induce, enhance or suppress the function of the immune system.

Myeloma Treatments

Daratumumab DARZALEX®

Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.

Learn more about this treatment


Ipilimumab

Ipilimumab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


Nivolumab

Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Learn more about this treatment


T Cells

A T cell or T lymphocyte is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity.

Learn more about this treatment


GSK2857916

GSK2857916 is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC).

Learn more about this treatment


SEA-BCMA

SEA-BCMA is a new antibody targeting the BCMA protein and being tested in multiple myeloma.

Learn more about this treatment


Atezolizumab

Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.

Learn more about this treatment


Cetuximab

Cetuximab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat colorectal cancer and squamous cell carcinoma of the head and neck. It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


SGN-CD48A

SGN-CD48A is a novel humanized anti-cd48 antibody-drug conjugate being tested for the treatment of multiple myeloma.

Learn more about this treatment


PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

Learn more about this treatment


bb2121

bb2121 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily. When it finds myeloma cells, bb2121 removes and destroys them.

Learn more about this treatment


BION-1301

BION-1301 is a humanized antibody that blocks A PRoliferation-Inducing Ligand (APRIL) from binding to its receptors, using Aduro’s B-select monoclonal antibody platform. In preclinical studies, BION-1301 eliminated malignant cells and reduced resistance to therapy in models of multiple myeloma.

Learn more about this treatment


Elotuzumab EMPLICITI®

Elotuzumab is a drug used for the treatment of multiple myeloma. It is for use in patients who have received one to three prior medications and is intended to be used in combination with lenalidomide and dexamethasone. It is given as an injection into a vein through an IV.

Learn more about this treatment


KITE-585

KITE-585 is a chimeric antigen receptor T-cell therapy. It targets a protein called B-cell maturation antigen, or BCMA, that is found on the surface of most multiple myeloma tumors.

Learn more about this treatment


Natural Killer (NK) Cells

Natural Killer Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).

Learn more about this treatment



Denosumab

Denosumab is a humanized monoclonal antibody that binds to RANKL and blocks the interaction of RANKL with RANK, resulting in inhibition of bone destroying cells and a decrease in bone breakdown.

Learn more about this treatment


TAK-079

TAK-079 is a fully human, non-agonistic, IgG1 cell-depleting monoclonal antibody that binds human CD38 with high affinity.

Learn more about this treatment


Isatuximab

SAR650984 is a humanized IgG1 monoclonal antibody that binds to CD38+ cells, triggerring antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and tumor programmed cell death.

Learn more about this treatment


Pembrolizumab

One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.

Learn more about this treatment


Measles Virus

Cancer treatment with the Measles Virus can work by modifying the virus to only infect cancer cells. Once injected into the body, the virus then can seek out and kill the cancer cells.

Learn more about this treatment


TTI-621

TTI-621 is a novel checkpoint inhibitor of the innate immune system, in relapsed or refractory hematologic malignancies.

Learn more about this treatment


MEDI7247

An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of MEDI7247 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.

Learn more about this treatment


Lintuzumab AC 225

Lintuzumab AC 225 is an Antibody Radio-Conjugate (ARC) comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the radioisotope actinium-225.

Learn more about this treatment


JNJ-68284528

JNJ-68284528 (LCAR-B38M) is an autologous CAR-T therapy that targets B-Cell Maturation Antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. The investigational therapy expresses an identical CAR protein as Legend's LCAR-B38M CAR-T product, which was evaluated in a first-in-human clinical study (Legend-2) conducted in multiple sites by Legend Biotech in China.

Learn more about this treatment


GBR 1342

GBR 1342 is a humanized, bispecific monoclonal antibody (bsAb) that is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors.

Learn more about this treatment


bb21217

bb21217 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily.

Learn more about this treatment


BFCR4350A

BFCR4350A is a bispecific T-cell engager (BiTE) antibody. It targets both the the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and as well as the CD3 antigen found on T lymphocytes.

Learn more about this treatment


JNJ-64007957

JNJ-64007957 is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.

Learn more about this treatment


AMG 701

AMG 701 is a bispecific antibody that targets both CD-3 and BCMA that is being tested in multiple myeloma.

Learn more about this treatment


SurVaxM

SurVaxM is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients’ own immune response to control tumor growth and recurrence.

Learn more about this treatment


Pneumococcal 13-Valent Conjugate Vaccine

Prevnar 13 is a vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae for the prevention of pneumococcal disease in immunocompromised patients with cancer.

Learn more about this treatment




AMG 224

AMG-224 is a new drug being tested in myeloma called an antibody-drug conjugate comprised of anti-BCMA–MCC–DM1. It consists of a chemotherapy drug combined with a monoclonal antibody which helps to deliver the drug to myeloma cells.

Learn more about this treatment


AMG 420

AMG 420 is made using Amgen’s proprietary BiTE or “bispecific T-cell engager” technology. AMG 420 consists of two proteins fused together, each designed to interact with a specific target — in this case, BCMA and CD3, a protein found on the surface of T-cells.

Learn more about this treatment


AMG 424

AMG 424 is a novel, humanized, bispecific T cell-recruiting anti-CD3/CD38 antibody.

Learn more about this treatment



CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells has the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity. CAR2 Anti-CD38 A2 CAR-T Cells are being evaluated in multiple myeloma (MM) and has successfully demonstrated strong preclinical anti-tumor activity in animal models.

Learn more about this treatment


CC-93269

CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.

Learn more about this treatment


Cemiplimab REGN2810

Cemiplimab REGN2810 is a fully human anti-PD-1 monoclonal antibody.

Learn more about this treatment


Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Learn more about this treatment


Durvalumab

Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to strengthen the patient's immune system and attack the cancer.

Learn more about this treatment


FOR46

FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46.

Learn more about this treatment


JCARH125

JCARH125 is a CAR T-cell product that targets B-cell maturation antigen (BCMA).

Learn more about this treatment


JNJ-64407564

JNJ-64407564 is a bispecific monoclonal antibody binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells.

Learn more about this treatment


MEDI2228

MEDI2228 is a novel antibody drug conjugate that targets BCMA.

Learn more about this treatment


PF-06863135

PF-06863135 is a B-cell Maturation Antigen (Bcma)-cd3 bispecific antibody being tested in multiple myeloma.

Learn more about this treatment


Reolysin

Reolysin is a serotype 3 Dearing strain (T3D) of reovirus that replicates and induces programmed tumor cell death in RAS-activated tumor cells.

Learn more about this treatment


SGN-CD352A

SGN-CD352A is an antibody drug conjugate that can work by targeting specific areas of the cancer cell, attacking it, and inducing rapid cell death.

Learn more about this treatment


SRF231

SRF231 is a fully human monoclonal antibody that targets and inhibits the activity of the CD47 protein that is highly expressed in cancer cells. CD47 works as a signal that prevents cancer cells from being recognized by the immune system and macrophages. By blocking CD47 signaling, SRF231 may allow macrophages to recognize and destroy cancer cells.

Learn more about this treatment


STRO-001

STRO-001 is an antibody drug conjugate targeting CD74, a cell surface protein associated with B-cell malignancies, including non-Hodgkin lymphoma and multiple myeloma.

Learn more about this treatment



Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;